-
Mashup Score: 0Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut - 7 month(s) ago
Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Final analysis of the #CLL2-GIVe trial: #obinutuzumab, #ibrutinib, and #venetoclax for untreated CLL with del(17p)/TP53mut 👉https://t.co/xKxTqFowPs @Blood @UniklinikUlm🇩🇪| #Multicenter https://t.co/nKHcjFeGkg